May 12, 2022 -- Cell and gene therapy (CGT) manufacturing is being hamstrung by bottlenecks that can be overcome by fully automating and standardizing the process, contends David Smith, vice president of technical operations at Ori Biotech.
Smith told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco that Ori Biotech has developed a digital platform that closes, automates, and standardizes CGT manufacturing to increase throughput, improve quality, and decrease costs.
"The industry is moving at such a rapid pace and there's a real challenge to keep up," Smith said. "There's so many facets of manufacturing that all have to come together in order for it to be successful."
Ori Biotech's goal is for its CGT manufacturing platform to enable therapy developers, contract manufacturers, and academic researchers to seamlessly transition from pre-clinical process discovery through clinical trials to commercial scale.
In January, Ori Biotech announced that it raised over $100 million in series B funding to add company personnel across all functions, ultimately leading to commercialization and launch of its platform.
Watch the video below to learn more.